Ocular hypotensive effects of anti-glaucoma agents in mice

Journal of Ocular Pharmacology and Therapeutics

Volumn 25, Issue 5, 2009, Pages 401-407

  Akaishi, Takahiro ^a   Odani Kawabata, Noriko ^a   Ishida, Naruhiro ^a   Nakamura, Masatsugu ^a  

^a SANTEN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; BRIMONIDINE; BUNAZOSIN; DIPIVEFRINE; DORZOLAMIDE; LATANOPROST; PILOCARPINE; SANPILO; TAFLUPROST; TIMOLOL; TIMOLOL MALEATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; INTRAOCULAR PRESSURE; MALE; MOUSE; NONHUMAN; PRESSURE MEASUREMENT;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; GLAUCOMA; INTRAOCULAR PRESSURE; MALE; MICE; MICE, INBRED STRAINS; MODELS, ANIMAL; OPHTHALMIC SOLUTIONS;

EID: 70350457930     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2009.0006     Document Type: Article

References (37)

1. Anderson, D.R. Glaucoma: The damage caused by pressure. XLVI Edward Jackson memorial lecture. Am. J. Ophthalmol. 108:485-495, 1989.
2. The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual fi eld deterioration. Am. J. Ophthalmol. 130:429-440, 2000.
3. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am. J. Ophthalmol. 126:498-505, 1998.
4. Orihashi, M., Shima, Y., Tsuneki, H., et al. Potent reduction of intraocular pressure by nipradilol plus latanoprost in ocular hypertensive rabbits. Biol. Pharm. Bull. 28:65-68, 2005.
5. Studer, M.E., Martin, C.L., and Stiles. J. Effects of 0.005% latanoprost solution on intraocular pressure in healthy dogs and cats. Am. J. Vet. Res. 61:1220-1224, 2000.
6. de Feo, G., Piccinelli, D., Putzolu, S., et al. Effects of topically instilled drugs on intraocular pressure in rabbits. Arzneimittelforschung. 25:806-809, 1975.
7. Pang, I.H., Wang, W.H., and Clark, A.F. Acute effects of glaucoma medications on rat intraocular pressure. Exp. Eye. Res. 80:207-214, 2005.
8. Takagi, Y., Nakajima, T., Shimazaki, A., et al. Pharmacological characteristics of AFP-168 (tafl uprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp. Eye Res. 78:767-776, 2004.
9. Toris, C.B., Camras, C.B., and Yablonski, M.E. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 100:1297-1304, 1993.
10. Lutjen-Drecoll, E. Normal morphology of the uveoscleral out- fl ow pathways. In: Alm, A., and Weinreb R.N., eds. Uveoscleral Outfl ow. London: Mosby-Wolfe, 1998:7-24.
11. Smith, R.S., Zabaleta, A., Savinova, O.V., et al. The mouse anterior chamber angle and trabecular meshwork develop without cell death. BioMed. Central. Dev. Biol. 1:3, 2001.
12. Aihara, M., Lindsey, J.D., and Weinreb, R.N. Aqueous humor dynamics in mice. Invest. Ophthalmol. Vis. Sci. 44:5168-5173, 2003.
13. Aihara, M., Lindsey, J.D., and Weinreb, R.N. Reduction of intraocular pressure in mouse eyes treated with latanoprost. Invest. Ophthalmol. Vis. Sci. 43:146-150, 2002.
14. Ota, T., Murata, H., Sugimoto, E., et al. Prostaglandin analogues and mouse intraocular pressure: Effects of tafl uprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation. Invest. Ophthalmol. Vis. Sci. 46:2006-2011, 2005.
15. Lederer, C., and Harold, R. Drop size of commercial glaucoma medications. Am. J. Ophthalmol. 101:691-694, 1986.
16. Toris, C.B, Yablonski, M.E., Wang, Y.L., et al. Aqueous humor dynamics in the aging human eye. Am. J. Ophthalmol. 127:407-412, 1999.
17. Distelhorst, J.S., and Hughes, G.M. Open-angle glaucoma. Am. Fam. Physician. 67:1937-1944, 2003.
18. McKinnon, S.J., Goldberg, L.D., Peeples, P., et al. Current management of glaucoma and the need for complete therapy. Am. J. Manag. Care. 14:S20-S27, 2008.
19. Tsukamoto, H., Jian, K., Takamatsu, M., et al. Additive effect of bunazosin on intraocular pressure when topically added to treatment with latanoprost in patients with glaucoma. Jpn. J. Ophthalmol. 47:526-528, 2003.
20. Kobayashi, H., Kobayashi, K., and Okinami, S. Effi cacy of bunazosin hydrochloride 0.01% as adjunctive therapy of latanoprost or timolol. J. Glaucoma. 13:73-80, 2004.
21. Akaishi, T., Takagi, Y., Matsugi, T., et al. Effects of bunazosin hydrochloride on ciliary muscle constriction and matrix metalloproteinase activities. J. Glaucoma. 13:312-318, 2004.
22. Townsend, D.J., and Brubaker, R.F. Immediate effect of epinephrine on aqueous formation in the normal human eye as measured by fl uorophotometry. Invest. Ophthalmol. Vis. Sci. 19:256-266, 1980.
23. Camras, C.B., Feldman, S.G., Podos, S.M., et al. Inhibition of the epinephrine-induced reduction of intraocular pressure by systemic indomethacin in humans. Am. J. Ophthalmol. 100:169-175, 1985.
24. Bill, A., and Phillips, C.I. Uveoscleral drainage of aqueous humour in human eyes. Exp. Eye Res. 12:275-281, 1971.
25. Toris, C.B., Gleason, M.L., Camras, C.B., et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 113:1514-1517, 1995.
26. Arici, M.K., Topalkara, A., and Guler, C. Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure. Int. Ophthalmol. 22:37-42, 1998.
27. Vanlandigham, B.D., and Brubaker, R.F. Combined effect of dorzolamide and latanoprost on the rate of aqueous humor fl ow. Am. J. Ophthalmol. 126:191-196, 1998.
28. Rulo, A.H., Greve, E.L., and Hoyng, P.F. Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure. Br. J. Ophthalmol. 78:899-902, 1994.
29. Alm, A., Widengard, I., Kjellgren, D., et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br. J. Ophthalmol. 79:12-16, 1995.
30. John, S.W., Anderson, M.G., and Smith, R.S. Mouse genetics: A tool to help unlock the mechanisms of glaucoma. J. Glaucoma. 8:400-412, 1999.
31. Zillig, M., Wurm, A., Grehn, F.J., et al. Overexpression and properties of wild-type and Tyr437His mutated myocilin in the eyes of transgenic mice. Invest. Ophthalmol. Vis. Sci. 46:223-234, 2005.
32. Shepard, A.R., Jacobson, N., Millar, J.C., et al. Glaucoma-causing myocilin mutants require the peroxisomal targeting signal-1 receptor (PTS1R) to elevate intraocular pressure. Hum. Mol. Genet. 16:609-617, 2007.
33. Avila, M.Y., Stone, R.A., and Civan, M.M. Knockout of A3 adenosine receptors reduces mouse intraocular pressure. Invest. Ophthalmol. Vis. Sci. 43:3021-3026, 2002
34. Crowston, J.G., Lindsey, J.D., Aihara, M., et al. Effect of latanoprost on intraocular pressure in mice lacking the prostaglandin FP receptor. Invest. Ophthalmol. Vis. Sci. 45:3555-3559, 2004.
35. Ota, T., Aihara, M., Narumiya, S., et al. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-defi cient mice. Invest. Ophthalmol. Vis. Sci. 46:4159-4163, 2005.
36. Ota, T., Aihara, M., Saeki, T., et al. The effects of prostaglandin analogues on prostanoid EP1, EP2, and EP3 receptor-defi cient mice. Invest. Ophthalmol. Vis. Sci. 47:3395-3399, 2006.
37. Ota, T., Aihara, M., Saeki, T., et al. The IOP-lowering effects and mechanism of action of tafl uprost in prostanoid receptor-defi - cient mice. Br. J. Ophthalmol. 91:673-676, 2007.